Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

Launched by FOX CHASE CANCER CENTER · Jun 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a chemotherapy treatment called gemcitabine and carboplatin (GC) can help people with advanced bladder or urinary tract cancer (urothelial carcinoma) who have already been treated with two other medicines, enfortumab vedotin and pembrolizumab (EVP). The researchers want to see if this chemotherapy can shrink the cancer or stop it from growing, how it affects patients’ survival and quality of life, and what side effects it may cause. They will also take blood samples to learn more about the cancer and how the treatment works in the body.

People eligible for this study must have advanced urothelial cancer that can be measured on scans, have already received EVP as their first treatment, and be generally healthy enough to receive chemotherapy (based on blood tests and overall condition). Participants will receive the GC chemotherapy and visit the clinic regularly for checkups, blood tests, and scans. They will also answer questions about their health and daily life, and provide blood samples for research. This study aims to find better treatment options for people with advanced bladder cancer, especially those who have tried other treatments before. It is currently not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must have metastatic or locally advanced histologically and radiographically confirmed urothelial carcinoma
• • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v1.1
• • Patients must have received treatment with enfortumab vedotin plus pembrolizumab in the first line setting. Study treatment may be started within 28 days of last treatment with EV-P or with continuing toxicities if considered by the Sponsor-Investigator to be safe and within the best interest of the patient.
• • Age \> 18 years.
• • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• • Patients must have normal organ and marrow function as defined below.
• • Absolute neutrophil count \> 1,000/mm3 unless patient has constitutional neutropenia
• • Platelets \> 80,000/ul
• • Hemoglobin \> 8.0 g/dL
• • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 x ULN or \<3.5 x upper limit of normal (ULN) if liver metastases
• • Creatinine Clearance \>20 mL/min
• • Ability to understand and willingness to sign a written informed consent and HIPAA consent document
• • Optional: Archival tumor biospecimen, when available, must be procured for correlative evaluation. If tumor tissue is not available or accessible despite good faith efforts, patient may still be treated on study. Formalin fixed paraffin embedded (FFPE) tissue block(s) or at least 15 unbaked, unstained slides are required. Tissue samples taken from a metastatic lesion prior to the start of screening are acceptable.
• Exclusion Criteria:
• • Patients who have had systemic treatment including EV-P or radiotherapy within 2 weeks prior to entering the study
• • Patients who have had systemic treatment including EV-P or radiotherapy within 2 weeks prior to entering the study
• • Patients who have received more than one line of prior therapy or prior platinum-based chemotherapy for locally advanced or metastatic urothelial carcinoma (neoadjuvant platinum-based therapy including cisplatin is allowed)
• • Patients who have not recovered from adverse events to less than Grade 2 secondary to agents administered more than 2 weeks prior to treatment initiation.
• • Patients may not be receiving any other investigational agents
• * Patients with uncontrolled and untreated CNS metastases:
• • Prior radiation to central nervous system (CNS) metastases is permitted
• • Prior history of CNS disease that has responded to previous systemic therapy is permitted only if no recurrence
• • Patient should not have leptomeningeal disease
• • CNS metastases have been clinically stable for at least 6 weeks prior to screening and baseline scans show no evidence of new or enlarged metastases
• • Uncontrolled intercurrent illness including, but not limited to ongoing or active untreated infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit adherence with study requirements
• • Subjects with a history of another invasive malignancy within 3 years before the first dose of study drug that cannot be watched and requires tumor- directed treatment, or any evidence of residual disease from a previously diagnosed malignancy that cannot be watched and requires treatment (adjuvant hormonal therapy for breast cancer is allowed)
• • Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of chemotherapy (routine antimicrobial prophylaxis is permitted)
• • Pregnant or breast feeding.